Everolimus Production Cost Reports

The report provides a detailed analysis essential for establishing an Everolimus production plant. It encompasses all critical aspects necessary for Everolimus production, including the cost of Everolimus production, Everolimus plant cost, Everolimus production costs, and the overall Everolimus production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Everolimus production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Everolimus is a macrolide immunosuppressant and mTOR inhibitor derived from rapamycin. It is mainly utilised in pharmaceutical production and medical device production. It functions as the active pharmaceutical ingredient (API) in the drug production sector for oral formulations like Afinitor tablets, used to treat advanced renal cell carcinoma, prevent organ transplant rejection, and manage conditions such as subependymal giant cell astrocytoma and neuroendocrine tumours.

Everolimus market growth is driven by rising global cancer incidence and increasing numbers of organ transplants, which expand demand for its use in oncology and immunosuppression. Factors such as ageing populations, better diagnosis rates, and wider clinical adoption in indications like renal cell carcinoma, neuroendocrine tumours, and breast cancer further propel market growth. Additionally, technological advances in targeted therapies, new oral formulations, and combination regimens enhance clinical value and support premium pricing, boosting the market demand.

Moreover, factors such as available strengths, formulations (tablets, dispersible, specialised devices like drug-eluting stents), stability and shelf life, compatibility with existing treatment protocols, and evolving clinical guidelines impact industrial everolimus procurement.

Raw Material for Everolimus Production

According to the Everolimus production plant project report, the raw material for Everolimus production includes sirolimus (rapamycin).

Production Process of Everolimus

The extensive Everolimus production cost report consists of the following major industrial production process:

1. Production via a semisynthetic route: The production process of Everolimus starts from sirolimus (rapamycin) produced via fermentation of Streptomyces hygroscopicus. The process involves regioselective O-alkylation at the C40 hydroxyl with a protected 2-hydroxyethyl group (e.g., TBDMSOCH2CH2OTf or similar triflate) in toluene/2,6-lutidine at 60 degree Celsius, yielding a protected intermediate compound. The next step involves deprotection of the intermediate by dissolving in ethyl acetate, cooling to 0-5 degree Celsius, adding 1 M HCl dropwise for selective hydrolysis (1-2 h), neutralising with NaHCO3, extracting with ethyl acetate, drying, and concentrating to produce the crude Everolimus. Additionally, purification uses ethyl acetate/anhydrous ether anti-solvent precipitation (20 mL each, stir 1 h, partial concentration), resuspension in ether (20 mL, 30 min), and drying.

Properties of Everolimus

Everolimus is a macrolide lactone immunosuppressant and mTOR inhibitor, chemically defined as 40-O-(2 hydroxyethyl) rapamycin with the molecular formula C53H83NO14 and a molecular weight of about 958.2 g/mol. It is a neutral, very weakly basic compound, classified as a macrolide with multiple alcohols, an ether, a cyclic ketone, and a lactone ring contributing to its reactivity and binding properties. It is a white to off white solid with high lipophilicity and very poor aqueous solubility, while being much more soluble in organic solvents such as ethanol, methanol, DMSO, and DMF, which drives the need for solid dispersion or other enabling oral formulations. It is generally stable under acidic conditions but susceptible to hydrolysis in alkaline media. It is photosensitive and therefore stored protected from light, and is kept at controlled room temperature to avoid degradation and maintain assay and impurity limits over shelf life.